Articles

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

Promotor hypermethylation of CpG islands is common in B cell precursor acute lymphoblastic leukemia (BCP-ALL) with mixed lineage leukemia (MLL) gene rearrangements. Hypomethylating agents (HMA) such as azaciti...

Authors: C. Roolf, A. Richter, C. Konkolefski, G. Knuebel, A. Sekora, S. Krohn, J. Stenzel, B. J. Krause, B. Vollmar, H. Murua Escobar and C. Junghanss

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9–13 months. Pediatric patien...

Authors: Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal and Anthony Stein

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells

Chimeric antigen receptor-engineered T (CAR-T) cells have extraordinary effect in treating lymphoblastic leukemia. However, treatment of acute myeloid leukemia (AML) using CAR-T cells remains limited to date. ...

Authors: Ying Wang, Yingxi Xu, Saisai Li, Jia Liu, Yanyan Xing, Haiyan Xing, Zheng Tian, Kejing Tang, Qing Rao, Min Wang and Jianxiang Wang

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery

Heat shock protein 90 (Hsp90) is a critical molecular chaperone protein that regulates the folding, maturation, and stability of a wide variety of proteins. In recent years, the development of Hsp90-directed i...

Authors: Ting Li, Hu-Lin Jiang, Yun-Guang Tong and Jin-Jian Lu

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first and rate-limiting step in converting tryptophan to kynurenine. Chimeric antigen receptor (CAR) T cells are T cells with recombinant receptors targeting ...

Authors: Qian Huang, Jiajia Xia, Lei Wang, Xu Wang, Xiaodong Ma, Qipan Deng, Yong Lu, Munish Kumar, Zhiyuan Zhou, Ling Li, Zhaoyang Zeng, Ken H. Young, Qing Yi, Mingzhi Zhang and Yong Li

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolum...

Authors: Yucai Wang, Grzegorz S. Nowakowski, Michael L. Wang and Stephen M. Ansell

Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a

The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK.

Authors: Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Kei-wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li, Kang-Shuai Li, Dong-Mei Gao, De-Ning Ma, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin…

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT

Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Eit...

Authors: Nicole Santoro, Myriam Labopin, Federica Giannotti, Gerard Ehninger, Dietger Niederwieser, Arne Brecht, Matthias Stelljes, Nicolaus Kröger, Herman Einsele, Matthias Eder, Michael Hallek, Bertram Glass, Jürgen Finke, Fabio Ciceri, Mohamad Mohty, Annalisa Ruggeri…

Exosomal miRNAs in hepatocellular carcinoma development and clinical responses

Hepatocellular carcinoma remains the sixth most lethal malignancy in the world. While HCC is often diagnosed via current biomarkers at a late stage, early detection of HCC has proven to be very difficult. Rece...

Authors: Shuangshuang Li, Jiping Yao, Mingjie Xie, Yanning Liu and Min Zheng

DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis

C-X-C motif ligand 8 (CXCL8), known as a proinflammatory chemokine, exerts multiple effects on the proliferation, invasion, and migration of tumor cells via the autocrine or paracrine manner. Conversely, the h...

Authors: Qian Liu, Anping Li, Shengnan Yu, Shuang Qin, Na Han, Richard G. Pestell, Xinwei Han and Kongming Wu

Expression levels of long non-coding RNAs are prognostic for AML outcome

Long non-coding RNA (lncRNA) expression has been implicated in a range of molecular mechanisms that are central in cancer. However, lncRNA expression has not yet been comprehensively characterized in acute mye...

Authors: Arvind Singh Mer, Johan Lindberg, Christer Nilsson, Daniel Klevebring, Mei Wang, Henrik Grönberg, Soren Lehmann and Mattias Rantalainen

Correction to: Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways

The original article [1] contains an inadvertent error in the following sentence in the Abstract regarding the erroneous description of Ser/Thr kinases as ‘phylogenetically related’:

Authors: Sabrina Manni, Marilena Carrino and Francesco Piazza

Increased B3GALNT2 in hepatocellular carcinoma promotes macrophage recruitment via reducing acetoacetate secretion and elevating MIF activity

Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third leading cause of tumor-related death, so it is urgently needed to discover efficient markers and targets for therapy. β-1,3-N-...

Authors: Tianxiao Yang, Yilin Wang, Wenjuan Dai, Xixi Zheng, Jing Wang, Shushu Song, Lan Fang, Jiangfan Zhou, Weicheng Wu and Jianxin Gu

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed mult...

Authors: Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel and Philippe Moreau

Multiple functions of m⁶A RNA methylation in cancer

First identified in 1974, m⁶A RNA methylation, which serves as a predominant internal modification of RNA in higher eukaryotes, has gained prodigious interest in recent years. Modifications of m⁶A are dynamic and...

Authors: Yutian Pan, Pei Ma, Yu Liu, Wei Li and Yongqian Shu

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, whic...

Authors: Ming Yi, Shengnan Yu, Shuang Qin, Qian Liu, Hanxiao Xu, Weiheng Zhao, Qian Chu and Kongming Wu

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models...

Authors: Rosemarie Tremblay-LeMay, Nasrin Rastgoo and Hong Chang

MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner

Fibroblasts are crucial mediators of tumor-stroma cross-talk through synthesis and remodeling of the extracellular matrix and production of multiple soluble factors. Nonetheless, little is still known about sp...

Authors: Francesca Andriani, Maria Teresa Majorini, Miguel Mano, Elena Landoni, Rosalba Miceli, Federica Facchinetti, Mavis Mensah, Enrico Fontanella, Matteo Dugo, Mauro Giacca, Ugo Pastorino, Gabriella Sozzi, Domenico Delia, Luca Roz and Daniele Lecis

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide

Chimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy. However, excessive activity and poor control over such ...

Authors: Erhao Zhang, Jieyi Gu, Jianpeng Xue, Chenyu Lin, Chen Liu, Mengwei Li, Jingchao Hao, Sarra Setrerrahmane, Xiaowei Chi, Weiyan Qi, Jialiang Hu and Hanmei Xu

The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an incurable B cell-derived malignant tumor with a median overall survival of 4–5 years. Mer tyrosine kinase (MerTK) has been reported to be aberrantly expressed in leukemia, mela...

Authors: Cunzhen Shi, Xiangqun Li, Xiaogan Wang, Ning Ding, Lingyan Ping, Yunfei Shi, Lan Mi, Yumei Lai, Yuqin Song and Jun Zhu

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

Myelofibrosis (MF) is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone marrow (BM) fibrosis. The oral Janus kinase (J...

Authors: Hans Michael Kvasnicka, Jürgen Thiele, Carlos E. Bueso-Ramos, William Sun, Jorge Cortes, Hagop M. Kantarjian and Srdan Verstovsek

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

The prognosis of adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal even at this day and age. With salvage chemotherapy, only 29% (range 18 to 44%) of the patients with R/R...

Authors: Li-Na Zhang, Yongping Song and Delong Liu

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from matched sibling donors (MSD) or unrelated donors (U...

Authors: Annalisa Ruggeri, Myriam Labopin, Andrea Bacigalupo, Boris Afanasyev, Jan J. Cornelissen, Ahmet Elmaagacli, Maija Itälä-Remes, Didier Blaise, Ellen Meijer, Yener Koc, Noel Milpied, Harry C. Schouten, Nicolaus Kroeger, Mohamad Mohty and Arnon Nagler

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response. In cancer, immune checkpoint pathways are often activated to inhibit the nascent ...

Authors: Julian A. Marin-Acevedo, Bhagirathbhai Dholaria, Aixa E. Soyano, Keith L. Knutson, Saranya Chumsri and Yanyan Lou

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

The original article [1] contained an error whereby Fig. 4 displayed incorrect magnification scales.

Authors: C. Festuccia, A. Mancini, A. Colapietro, G. L. Gravina, F. Vitale, F. Marampon, S. Delle Monache, S. Pompili, L. Cristiano, A. Vetuschi, V. Tombolini, Y. Chen and T. Mehrling

Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

The original article [1] contained an error in Table 1 whereby the ‘Positive’ column in the ‘PD-L1’ Tumor type group of columns was mistakenly included at the beginning of the ‘PD-L2’ Tumor type group of columns.

Authors: Bingxin Zheng, Tingting Ren, Yi Huang, Kunkun Sun, Shidong Wang, Xing Bao, Kuisheng Liu and Wei Guo

A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase

Protein tyrosine phosphatase of regenerating liver 3 (PRL-3) is overexpressed in a subset of AML patients with inferior prognosis, representing an attractive therapeutic target. However, due to relatively shal...

Authors: Jianbiao Zhou, Sabrina Hui-Min Toh, Zit-Liang Chan, Jessie Yiying Quah, Jing-Yuan Chooi, Tuan Zea Tan, Phyllis S. Y. Chong, Qi Zeng and Wee-Joo Chng

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Anti-CD19 CAR T cell therapy has demonstrated high response rates in patients with relapsed or refractory (r/r) B cell malignancies but is associated with significant toxicity. Cytokine release syndrome (CRS) ...

Authors: David Porter, Noelle Frey, Patricia A. Wood, Yanqiu Weng and Stephan A. Grupp

Standardizing haematopoietic cell transplants in China

Authors: Robert Peter Gale

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant hematological neoplasms and non-malignant hematological disorders. Approximately, 5000 allo-HSCT procedures are ...

Authors: Lanping Xu, Hu Chen, Jing Chen, Mingzhe Han, He Huang, Yongrong Lai, Daihong Liu, Qifa Liu, Ting Liu, Ming Jiang, Hanyun Ren, Yongping Song, Zimin Sun, Jianmin Wang, Depei Wu, Daobin Zhou…

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of ...

Authors: Claudio Festuccia, Andrea Mancini, Alessandro Colapietro, Giovanni Luca Gravina, Flora Vitale, Francesco Marampon, Simona Delle Monache, Simona Pompili, Loredana Cristiano, Antonella Vetuschi, Vincenzo Tombolini, Yi Chen and Thomas Mehrling

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

The advent of immunotherapy, especially checkpoint inhibitor-based immunotherapy, has provided novel and powerful weapons against cancer. Because only a subset of cancer patients exhibit durable responses, fur...

Authors: Xiaolei Li, Changshun Shao, Yufang Shi and Weidong Han

CAMKs support development of acute myeloid leukemia

We recently identified the human leukocyte immunoglobulin-like receptor B2 (LILRB2) and its mouse ortholog-paired Ig-like receptor (PirB) as receptors for several angiopoietin-like proteins (Angptls). We also ...

Authors: Xunlei Kang, Changhao Cui, Chen Wang, Guojin Wu, Heyu Chen, Zhigang Lu, Xiaoli Chen, Li Wang, Jie Huang, Huimin Geng, Meng Zhao, Zhengshan Chen, Markus Müschen, Huan-You Wang and Cheng Cheng Zhang

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bor...

Authors: Zhihong Zheng, Shengjun Fan, Jing Zheng, Wei Huang, Cristina Gasparetto, Nelson J. Chao, Jianda Hu and Yubin Kang

NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells

This study was performed to investigate the role of nucleotide-binding oligomerization domain (NOD)-like receptor X1 (NLRX1) in regulating hepatocellular carcinoma (HCC) progression.

Authors: Bo Hu, Guang-Yu Ding, Pei-Yao Fu, Xiao-Dong Zhu, Yuan Ji, Guo-Ming Shi, Ying-Hao Shen, Jia-Bin Cai, Zhen Yang, Jian Zhou, Jia Fan, Hui-Chuan Sun, Ming Kuang and Cheng Huang

The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis

Adenosine triphosphate (ATP)-dependent chromatin remodeling SWI/SNF-like BAF and PBAF complexes have been implicated in the regulation of stem cell function and cancers. Several subunits of BAF or PBAF, includ...

Authors: Lulu Liu, Xiaoling Wan, Peipei Zhou, Xiaoyuan Zhou, Wei Zhang, Xinhui Hui, Xiujie Yuan, Xiaodan Ding, Ruihong Zhu, Guangxun Meng, Hui Xiao, Feng Ma, He Huang, Xianmin Song, Bin Zhou, Sidong Xiong…

Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer

Resistance to tamoxifen (TAM) frequently occurs in the treatment of estrogen receptor positive (ER+) breast cancer. Accumulating evidences indicate that transcription factor HOXB13 is of great significance in ...

Authors: Bowen Liu, Tianjiao Wang, Huawei Wang, Lu Zhang, Feifei Xu, Runping Fang, Leilei Li, Xiaoli Cai, Yue Wu, Weiying Zhang and Lihong Ye

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia

Anti-CD19 chimeric antigen receptor (CAR) T cells have shown promise in the treatment of B cell acute lymphocytic leukemia (B-ALL). However, its efficacy in B-ALL patients with extramedullary involvement is li...

Authors: Jianyu Weng, Peilong Lai, Le Qin, Yunxin Lai, Zhiwu Jiang, Chenwei Luo, Xin Huang, Suijing Wu, Dan Shao, Chengxin Deng, Lisi Huang, Zesheng Lu, Maohua Zhou, Lingji Zeng, Dongmei Chen, Yulian Wang…

Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer

GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes an...

Authors: Alessandra Metelli, Mohammad Salem, Caroline H. Wallace, Bill X. Wu, Anqi Li, Xue Li and Zihai Li

Artesunate shows potent anti-tumor activity in B-cell lymphoma

Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identif...

Authors: Thea Kristin Våtsveen, Marit Renée Myhre, Chloé Beate Steen, Sébastien Wälchli, Ole Christian Lingjærde, Baoyan Bai, Pierre Dillard, Theodossis A. Theodossiou, Toril Holien, Anders Sundan, Else Marit Inderberg, Erlend B. Smeland, June Helen Myklebust and Morten P. Oksvold

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic leukemia. While CAR-T has achi...

Authors: Jian Li, Wenwen Li, Kejia Huang, Yang Zhang, Gary Kupfer and Qi Zhao

Circular RNAs: a new frontier for cancer diagnosis and therapy

In recent years, circular RNAs (circRNAs) have attracted considerable attention because they play a significant role in many fields of cancer biology. Additionally, it has become increasingly clear that circRN...

Authors: Miaoci Zhang and Yan Xin

Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Patient-derived xenograft (PDX) models with definite molecular signature are attractive preclinical models for development of novel targeted drugs. Here, we profiled and explored potential therapeutic targets ...

Authors: Zuhua Chen, Wenwen Huang, Tiantian Tian, Wanchun Zang, Jingyuan Wang, Zhentao Liu, Zhongwu Li, Yumei Lai, Zhi Jiang, Jing Gao and Lin Shen

SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS

SF3B1 is a core component of splicing machinery. Mutations in SF3B1 are frequently found in myelodysplastic syndromes (MDS), particularly in patients with refractory anemia with ringed sideroblasts (RARS), cha...

Authors: Yumin Huang, John Hale, Yaomei Wang, Wei Li, Shijie Zhang, Jieying Zhang, Huizhi Zhao, Xinhua Guo, Jing Liu, Hongxia Yan, Karina Yazdanbakhsh, Gang Huang, Christopher D. Hillyer, Narla Mohandas, Lixiang Chen, Ling Sun…

Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population

Racial and ethnic disparities in malignancies attract extensive attention. To investigate whether there are racial and ethnic disparities in genetic alteration between Caucasian and Eastern Asian population, d...

Authors: Hui Wei, Ying Wang, Chunlin Zhou, Dong Lin, Bingcheng Liu, Kaiqi Liu, Shaowei Qiu, Benfa Gong, Yan Li, Guangji Zhang, Shuning Wei, Xiaoyuan Gong, Yuntao Liu, Xingli Zhao, Runxia Gu, Yingchang Mi…

CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways

Chromobox protein homolog 7 (CBX7), a member of the polycomb group (PcG) family of proteins, is involved in the regulation of cell proliferation and cancer progression. PcG family members, such as BMI, Mel-18,...

Authors: Su-Jie Ni, Li-Qin Zhao, Xiao-Feng Wang, Zhen-Hua Wu, Rui-Xi Hua, Chun-Hua Wan, Jie-Yun Zhang, Xiao-Wei Zhang, Ming-Zhu Huang, Lu Gan, Hua-Lin Sun, Goberdhan P. Dimri and Wei-Jian Guo

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

Immune checkpoint inhibitors have led to a breakthrough in solid tumor immunotherapy, but related studies on musculoskeletal tumors are few, especially for PD-L2.

Authors: Bingxin Zheng, Tingting Ren, Yi Huang, Kunkun Sun, Shidong Wang, Xing Bao, Kuisheng Liu and Wei Guo

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma that is associated with a poor outcome. Currently, the treatment needs of NKTCL remain unmet, and efforts to further improve tre...

Authors: Xin Li, Yasong Cheng, Mingzhi Zhang, Jiaqin Yan, Ling Li, Xiaorui Fu, Xudong Zhang, Yu Chang, Zhenchang Sun, Hui Yu, Lei Zhang, Xinhua Wang, Jingjing Wu, Zhaoming Li, Feifei Nan, Li Tian…

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)the...

Authors: Yiyin Zhang, Chao Yang, He Cheng, Zhiyao Fan, Qiuyi Huang, Yu Lu, Kun Fan, Guopei Luo, Kaizhou Jin, Zhengshi Wang, Chen Liu and Xianjun Yu

Current trials for frontline therapy of mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare and incurable subtype of non-Hodgkin’s lymphoma that generally affects older individuals. However, the use of high-dose therapy and autologous stem cell transplant has impr...

Authors: Raphael E. Steiner, Jorge Romaguera and Michael Wang